These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. [Questions and answers about bisphosphonates]. Letonturier P Presse Med; 2007 Mar; 36(3 Pt 1):440. PubMed ID: 17436449 [No Abstract] [Full Text] [Related]
15. A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years. Reid IR; Lyles K; Su G; Brown JP; Walsh JP; del Pino-Montes J; Miller PD; Fraser WD; Cafoncelli S; Bucci-Rechtweg C; Hosking DJ J Bone Miner Res; 2011 Sep; 26(9):2261-70. PubMed ID: 21638319 [TBL] [Abstract][Full Text] [Related]
16. Response to publication of PRISM trial. Reid IR; Cundy T; Bolland MJ; Grey A J Bone Miner Res; 2010 Jun; 25(6):1463-4; author reply 1465-6. PubMed ID: 20499373 [No Abstract] [Full Text] [Related]
17. The use of intravenous aminobisphosphonates for the treatment of Paget's disease of bone. Gennari L; Merlotti D; Mossetti G; Rendina D; De Paola V; Martini G; Nuti R Mini Rev Med Chem; 2009 Aug; 9(9):1052-63. PubMed ID: 19689402 [TBL] [Abstract][Full Text] [Related]
18. Emerging issues with bisphosphonates. Reid IR Rheum Dis Clin North Am; 2006 Nov; 32(4):691-702, vi. PubMed ID: 17288972 [TBL] [Abstract][Full Text] [Related]
19. [Intravenous bisphosphonates for bone Paget's disease: higher risk of adverse events]. Grados D; Martínez-Morillo M; Holgado S; Erra A Med Clin (Barc); 2014 May; 142(10):469-70. PubMed ID: 24120108 [No Abstract] [Full Text] [Related]
20. Paget's disease. Common cause of bone weakening. Mayo Clin Health Lett; 2013 Jun; 31(6):7. PubMed ID: 24716278 [No Abstract] [Full Text] [Related] [Next] [New Search]